BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20884844)

  • 1. Brain-penetrating tumor necrosis factor decoy receptor in the mouse.
    Zhou QH; Boado RJ; Hui EK; Lu JZ; Pardridge WM
    Drug Metab Dispos; 2011 Jan; 39(1):71-6. PubMed ID: 20884844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor.
    Zhou QH; Sumbria R; Hui EK; Lu JZ; Boado RJ; Pardridge WM
    J Pharmacol Exp Ther; 2011 Nov; 339(2):618-23. PubMed ID: 21831964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein.
    Sumbria RK; Boado RJ; Pardridge WM
    J Cereb Blood Flow Metab; 2012 Oct; 32(10):1933-8. PubMed ID: 22714051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein.
    Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
    J Biotechnol; 2010 Mar; 146(1-2):84-91. PubMed ID: 20100527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease.
    Chang R; Knox J; Chang J; Derbedrossian A; Vasilevko V; Cribbs D; Boado RJ; Pardridge WM; Sumbria RK
    Mol Pharm; 2017 Jul; 14(7):2340-2349. PubMed ID: 28514851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice.
    Sumbria RK; Zhou QH; Hui EK; Lu JZ; Boado RJ; Pardridge WM
    Mol Pharm; 2013 Apr; 10(4):1425-31. PubMed ID: 23410508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse.
    Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Drug Metab Dispos; 2010 Apr; 38(4):566-72. PubMed ID: 20075191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic TNFα-inhibitors that cross the human blood-brain barrier.
    Pardridge WM
    Bioeng Bugs; 2010; 1(4):231-4. PubMed ID: 21327054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor.
    Boado RJ; Zhou QH; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2010 Feb; 7(1):237-44. PubMed ID: 19921848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.
    Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2010 Dec; 7(6):2148-55. PubMed ID: 20860349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination stroke therapy in the mouse with blood-brain barrier penetrating IgG-GDNF and IgG-TNF decoy receptor fusion proteins.
    Sumbria RK; Boado RJ; Pardridge WM
    Brain Res; 2013 Apr; 1507():91-6. PubMed ID: 23428543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
    Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody.
    Pardridge WM
    Expert Opin Drug Deliv; 2015 Feb; 12(2):207-22. PubMed ID: 25138991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
    Pardridge WM; Boado RJ
    Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse.
    Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Drug Metab Dispos; 2012 Feb; 40(2):329-35. PubMed ID: 22065691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein.
    Zhou QH; Lu JZ; Hui EK; Boado RJ; Pardridge WM
    Bioconjug Chem; 2011 Aug; 22(8):1611-8. PubMed ID: 21707084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.
    Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
    Mol Pharm; 2011 Aug; 8(4):1342-50. PubMed ID: 21667973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier.
    Hui EK; Boado RJ; Pardridge WM
    Mol Pharm; 2009; 6(5):1536-43. PubMed ID: 19624167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse.
    Boado RJ; Zhang Y; Wang Y; Pardridge WM
    Biotechnol Bioeng; 2009 Mar; 102(4):1251-8. PubMed ID: 18942151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse.
    Zhou QH; Hui EK; Lu JZ; Boado RJ; Pardridge WM
    Brain Res; 2011 Mar; 1382():315-20. PubMed ID: 21276430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.